CH645893A5 - Cytostatisch wirkende arzneimittel. - Google Patents
Cytostatisch wirkende arzneimittel. Download PDFInfo
- Publication number
- CH645893A5 CH645893A5 CH143980A CH143980A CH645893A5 CH 645893 A5 CH645893 A5 CH 645893A5 CH 143980 A CH143980 A CH 143980A CH 143980 A CH143980 A CH 143980A CH 645893 A5 CH645893 A5 CH 645893A5
- Authority
- CH
- Switzerland
- Prior art keywords
- compounds
- days
- treatment
- hydrogen
- tgi
- Prior art date
Links
- 229940126601 medicinal product Drugs 0.000 title claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000001257 hydrogen Substances 0.000 claims abstract description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 8
- 230000001085 cytostatic effect Effects 0.000 claims abstract description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 5
- 239000000126 substance Substances 0.000 claims abstract description 5
- 230000002152 alkylating effect Effects 0.000 claims abstract description 3
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims abstract description 3
- 125000000217 alkyl group Chemical group 0.000 claims abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 208000032839 leukemia Diseases 0.000 claims description 6
- OUPZKGBUJRBPGC-IWSPIJDZSA-N 1,3,5-tris[[(2r)-oxiran-2-yl]methyl]-1,3,5-triazinane-2,4,6-trione Chemical compound O=C1N(C[C@H]2OC2)C(=O)N(C[C@H]2OC2)C(=O)N1C[C@@H]1CO1 OUPZKGBUJRBPGC-IWSPIJDZSA-N 0.000 claims description 5
- 239000000824 cytostatic agent Substances 0.000 claims description 4
- 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 3
- 230000001472 cytotoxic effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 2
- OUPZKGBUJRBPGC-UHFFFAOYSA-N 1,3,5-tris(oxiran-2-ylmethyl)-1,3,5-triazinane-2,4,6-trione Chemical compound O=C1N(CC2OC2)C(=O)N(CC2OC2)C(=O)N1CC1CO1 OUPZKGBUJRBPGC-UHFFFAOYSA-N 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 125000003700 epoxy group Chemical group 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 229960004961 mechlorethamine Drugs 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- ZFSLODLOARCGLH-UHFFFAOYSA-N isocyanuric acid Chemical compound OC1=NC(O)=NC(O)=N1 ZFSLODLOARCGLH-UHFFFAOYSA-N 0.000 abstract description 10
- 239000000203 mixture Substances 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- SNKDCTFPQUHAPR-UHFFFAOYSA-N 1-fluoropyrimidine-2,4-dione Chemical compound FN1C=CC(=O)NC1=O SNKDCTFPQUHAPR-UHFFFAOYSA-N 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 238000007912 intraperitoneal administration Methods 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000004593 Epoxy Substances 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical compound COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 description 2
- LULAYUGMBFYYEX-UHFFFAOYSA-N 3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000005394 methallyl group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- GKKCIDNWFBPDBW-UHFFFAOYSA-M potassium cyanate Chemical compound [K]OC#N GKKCIDNWFBPDBW-UHFFFAOYSA-M 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- OUPZKGBUJRBPGC-HLTSFMKQSA-N 1,5-bis[[(2r)-oxiran-2-yl]methyl]-3-[[(2s)-oxiran-2-yl]methyl]-1,3,5-triazinane-2,4,6-trione Chemical compound O=C1N(C[C@H]2OC2)C(=O)N(C[C@H]2OC2)C(=O)N1C[C@H]1CO1 OUPZKGBUJRBPGC-HLTSFMKQSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- OHXAOPZTJOUYKM-UHFFFAOYSA-N 3-Chloro-2-methylpropene Chemical compound CC(=C)CCl OHXAOPZTJOUYKM-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- KOVAQMSVARJMPH-UHFFFAOYSA-N 4-methoxybutan-1-ol Chemical compound COCCCCO KOVAQMSVARJMPH-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 201000008228 Ependymoblastoma Diseases 0.000 description 1
- 206010014968 Ependymoma malignant Diseases 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000007093 Leukemia L1210 Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- OJYGBLRPYBAHRT-UHFFFAOYSA-N alphachloralose Chemical compound O1C(C(Cl)(Cl)Cl)OC2C(O)C(C(O)CO)OC21 OJYGBLRPYBAHRT-UHFFFAOYSA-N 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000003327 cancerostatic effect Effects 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000006735 epoxidation reaction Methods 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- -1 glycol ethers Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 229910001510 metal chloride Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2907349A DE2907349C2 (de) | 1979-02-24 | 1979-02-24 | Arzneimittel mit cytostatischer Wirksamkeit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH645893A5 true CH645893A5 (de) | 1984-10-31 |
Family
ID=6063886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH143980A CH645893A5 (de) | 1979-02-24 | 1980-02-22 | Cytostatisch wirkende arzneimittel. |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0014981B1 (enExample) |
| JP (1) | JPS55118484A (enExample) |
| AT (1) | ATE716T1 (enExample) |
| AU (1) | AU536270B2 (enExample) |
| BE (1) | BE881834A (enExample) |
| CA (1) | CA1123740A (enExample) |
| CH (1) | CH645893A5 (enExample) |
| DE (1) | DE2907349C2 (enExample) |
| FR (1) | FR2449451A1 (enExample) |
| GB (1) | GB2044614B (enExample) |
| IE (1) | IE49274B1 (enExample) |
| IL (1) | IL59453A (enExample) |
| IT (1) | IT1147330B (enExample) |
| LU (1) | LU82190A1 (enExample) |
| NL (1) | NL8001100A (enExample) |
| NZ (1) | NZ192945A (enExample) |
| SE (1) | SE8001425L (enExample) |
| ZA (1) | ZA801017B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT371816B (de) * | 1979-10-08 | 1983-08-10 | Henkel Kgaa | Verfahren zur herstellung von neuen isocyanurs[urederivaten |
| EP0033503B1 (de) * | 1980-01-31 | 1986-09-10 | Henkel Kommanditgesellschaft auf Aktien | Arzneimittel mit cytostatischer Wirkung sowie Verwendung von mehrfach mit Glycidylgruppen substituierten N-heterocyclischen Ringverbindungen in pharmazeutischen Zubereitungen |
| AT372382B (de) * | 1980-08-14 | 1983-09-26 | Henkel Kgaa | Verfahren zur herstellung von neuen oxiranylisocyanursaeureverbindungen |
| DE3131365A1 (de) * | 1981-08-07 | 1983-02-24 | Henkel KGaA, 4000 Düsseldorf | Neue diglycidyl-substituierte heterocyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung in arzneimittelzubereitungen mit cytostatischer wirksamkeit |
| DE3131396A1 (de) * | 1981-08-07 | 1983-03-24 | Henkel KGaA, 4000 Düsseldorf | "neue diglycidyl-pteridin-verbindungen, verfahren zu ihrer herstellung und ihre anwendung in arzneimitteln mit cytostatischer wirkung" |
| DE3133077A1 (de) * | 1981-08-21 | 1983-03-10 | Henkel KGaA, 4000 Düsseldorf | Neue cytostatisch wirksame epoxidgruppen tragende 1,3,2-oxazaphosphorin-verbindungen, verfahren zu ihrer herstellung sowie ihre verwendung in pharmazeutischen zubereitungen |
| TWI243169B (en) * | 1998-03-02 | 2005-11-11 | Nissan Chemical Ind Ltd | Optically active epoxy compound |
-
1979
- 1979-02-24 DE DE2907349A patent/DE2907349C2/de not_active Expired
-
1980
- 1980-02-18 EP EP80100806A patent/EP0014981B1/de not_active Expired
- 1980-02-18 AT AT80100806T patent/ATE716T1/de not_active IP Right Cessation
- 1980-02-21 BE BE0/199482A patent/BE881834A/fr not_active IP Right Cessation
- 1980-02-22 GB GB8006109A patent/GB2044614B/en not_active Expired
- 1980-02-22 NZ NZ192945A patent/NZ192945A/en unknown
- 1980-02-22 CH CH143980A patent/CH645893A5/de not_active IP Right Cessation
- 1980-02-22 IE IE362/80A patent/IE49274B1/en unknown
- 1980-02-22 AU AU55830/80A patent/AU536270B2/en not_active Ceased
- 1980-02-22 SE SE8001425A patent/SE8001425L/ not_active Application Discontinuation
- 1980-02-22 ZA ZA00801017A patent/ZA801017B/xx unknown
- 1980-02-22 FR FR8003962A patent/FR2449451A1/fr active Granted
- 1980-02-22 NL NL8001100A patent/NL8001100A/nl not_active Application Discontinuation
- 1980-02-22 IT IT20100/80A patent/IT1147330B/it active
- 1980-02-22 IL IL59453A patent/IL59453A/xx unknown
- 1980-02-22 LU LU82190A patent/LU82190A1/de unknown
- 1980-02-23 JP JP2214580A patent/JPS55118484A/ja active Granted
- 1980-02-25 CA CA346,385A patent/CA1123740A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| ATE716T1 (de) | 1982-03-15 |
| AU536270B2 (en) | 1984-05-03 |
| DE2907349C2 (de) | 1982-09-16 |
| FR2449451B1 (enExample) | 1982-12-10 |
| IL59453A0 (en) | 1980-05-30 |
| EP0014981A2 (de) | 1980-09-03 |
| DE2907349A1 (de) | 1980-08-28 |
| EP0014981B1 (de) | 1982-02-24 |
| IT8020100A0 (it) | 1980-02-22 |
| JPS55118484A (en) | 1980-09-11 |
| GB2044614B (en) | 1983-01-26 |
| LU82190A1 (de) | 1980-09-24 |
| IE49274B1 (en) | 1985-09-04 |
| BE881834A (fr) | 1980-08-21 |
| NL8001100A (nl) | 1980-08-26 |
| IL59453A (en) | 1984-02-29 |
| GB2044614A (en) | 1980-10-22 |
| NZ192945A (en) | 1984-05-31 |
| ZA801017B (en) | 1981-02-25 |
| FR2449451A1 (fr) | 1980-09-19 |
| IT1147330B (it) | 1986-11-19 |
| IE800362L (en) | 1980-08-24 |
| AU5583080A (en) | 1980-09-04 |
| JPS6354688B2 (enExample) | 1988-10-28 |
| SE8001425L (sv) | 1980-08-25 |
| CA1123740A (en) | 1982-05-18 |
| EP0014981A3 (en) | 1981-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0240829B1 (de) | Cancerostatisches Mittel | |
| DE2525633A1 (de) | Daunomycinanaloga | |
| DE3042120A1 (de) | 5-fluoruracil-derivate | |
| DE69415507T2 (de) | Analoge von acylfulven als antitumormittel | |
| DE2707934C2 (enExample) | ||
| DD157797A5 (de) | Verfahren zur herstellung von substituierten 9,10-anthracen-bishydrazonen | |
| EP0014981B1 (de) | Cytostatisch wirkende Arzneimittel bzw. pharmazeutische Zubereitungen | |
| DE2627146B2 (de) | Adriamycinester, Verfahren zu deren Herstellung und pharmazeutische Mittel enthaltend diese Adriamycinester | |
| DE2953309C2 (de) | Cytostatisch wirkende Arzneimittel beziehungsweise pharmazeutische Zubereitungen | |
| EP0033503B1 (de) | Arzneimittel mit cytostatischer Wirkung sowie Verwendung von mehrfach mit Glycidylgruppen substituierten N-heterocyclischen Ringverbindungen in pharmazeutischen Zubereitungen | |
| DE3043437C2 (enExample) | ||
| DE3134709A1 (de) | Antineoplastisch wirkende titanverbindung und diese enthaltende arzneimittel | |
| CH636874A5 (de) | Verfahren zur herstellung von neuen 5-fluoruracilderivaten und nach dem verfahren hergestellte 5-fluoruracilderivate. | |
| DE1965711B2 (de) | l^-Dihydro-133-triazin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel | |
| DD140250A5 (de) | Verfahren zur herstellung von hydrazon-verbindungen | |
| DE68928802T2 (de) | 1,2,4-benzotriazin-n-oxidderivate als radiosensibilisierende und selektive cytotoxische mittel | |
| DE3003356A1 (de) | Arzneimittel mit cytostatischer wirkung sowie verwendung von glycidyl-glykolurilverbindungen in pharmazeutischen zubereitungen | |
| DE3116250A1 (de) | "nonaprenylamin-derivate und sie enthaltende pharmazeutische mittel" | |
| DE3514455A1 (de) | Arzneimittel mit cytostatischer wirksamkeit, enthaltend glycidylamine | |
| DE2314387A1 (de) | Arzneimittel zur behandlung boesartiger neubildungen, vorzugsweise von haemoblastosen und chorionepitheliom | |
| DE10138561A1 (de) | Tumorhemmende Cerverbindungen | |
| EP0071903B1 (de) | Neue Diglycidyl-pteridin-Verbindungen, Verfahren zu ihrer Herstellung und ihre Anwendung in Arzneimitteln mit cytostatischer Wirkung | |
| DE10114106C1 (de) | Tumorhemmende Siliciumverbindungen, Verfahren zu ihrer Herstellung und deren Verwendung als Arzneimittel | |
| AT370729B (de) | Verfahren zur herstellung von neuen diglycidyltriazinverbindungen | |
| DE1595901C (de) | 2-Azetidinone und Verfahren zu ihrer Herstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |